Critical Illness Effects on Ovarian Function

Abstract

Critical illness exerts profound effects on ovarian function, with implications for reproductive health, hormonal regulation, and long-term fertility in women of reproductive age. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical manifestations, and management of ovarian dysfunction secondary to acute critical illness. The discussion integrates recent advances, emerging therapies, and guideline-based recommendations, aiming to equip clinicians with a comprehensive understanding for optimizing patient outcomes.

Introduction

Critical illness, encompassing severe infections, trauma, sepsis, and multi-organ dysfunction, triggers complex physiological responses that can impact multiple organ systems, including the female reproductive axis. The hypothalamic-pituitary-ovarian (HPO) axis is particularly susceptible to the metabolic, inflammatory, and neuroendocrine disturbances characteristic of critical illness. Disruption of ovarian function in this context poses significant challenges for clinical care, especially in women desiring future fertility or those in whom hormonal homeostasis is crucial for overall health. Understanding the mechanisms, clinical presentation, and management of ovarian dysfunction in critically ill patients is essential for providing holistic and evidence-based care.

Epidemiology / Disease Burden

The prevalence of ovarian dysfunction in critically ill women varies widely, with amenorrhea and menstrual irregularities reported in up to 60% of cases during or after intensive care unit (ICU) admission. Studies indicate that acute ovarian suppression is often transient, but persistent dysfunction can occur, particularly in patients with prolonged critical illness, severe systemic inflammation, or multi-organ failure. The burden is compounded by increasing survival rates among young women following critical illness, leading to a growing population at risk for reproductive sequelae. Epidemiological data highlight a need for systematic assessment of ovarian function in this patient cohort, given the potential impacts on quality of life and fertility.

Pathophysiology

The pathogenesis of ovarian dysfunction in critical illness is multifactorial. Disruption of the HPO axis is central, with decreased pulsatile gonadotropin-releasing hormone (GnRH) secretion due to stress, cytokine release, and altered neuroendocrine signaling. Elevated cortisol and catecholamines suppress pituitary gonadotropins (LH and FSH), impairing folliculogenesis and ovulation. Direct ovarian injury may result from hypoperfusion, ischemia, or microvascular thrombosis in the context of shock or disseminated intravascular coagulation. Inflammatory cytokines such as IL-6 and TNF-α further inhibit ovarian steroidogenesis. Medications frequently used in the ICU, including opioids, vasopressors, and corticosteroids, may exacerbate HPO axis suppression. These mechanisms collectively contribute to menstrual disturbances, hypoestrogenism, and, in severe cases, premature ovarian insufficiency (POI).

Risk Factors

Key risk factors for ovarian dysfunction in the critically ill include the severity and duration of illness, underlying comorbidities (e.g., autoimmune diseases, malignancy), extremes of age, nutritional deficits, and exposure to gonadotoxic agents (chemotherapy, radiation). Patients with sepsis, multi-organ failure, or those undergoing prolonged mechanical ventilation are at particularly high risk. Pre-existing reproductive endocrine disorders, such as polycystic ovary syndrome (PCOS) or diminished ovarian reserve, may amplify susceptibility to acute ovarian dysfunction. Additionally, the use of certain medications—such as high-dose corticosteroids or immunosuppressants—can further impair ovarian function.

Clinical Features

Clinical manifestations of ovarian dysfunction during or following critical illness are variable. The most common presentation is amenorrhea or oligomenorrhea, often with associated symptoms of hypoestrogenism such as vasomotor instability, sleep disturbances, mood changes, and vaginal dryness. Laboratory findings typically reveal low estradiol levels with inappropriately low or normal gonadotropins, consistent with hypogonadotropic hypogonadism. In some cases, features of POI may emerge, including elevated FSH and LH with persistent amenorrhea. The diagnosis may be complicated by confounding factors such as nutritional status, weight fluctuations, and coexisting endocrine disturbances.

Diagnosis

Diagnosis of ovarian dysfunction in critically ill patients requires a high index of suspicion and systematic evaluation. Assessment should begin with a detailed menstrual and reproductive history, followed by measurement of serum gonadotropins (FSH, LH), estradiol, and, where indicated, anti-Müllerian hormone (AMH) to evaluate ovarian reserve. Thyroid function, prolactin, and adrenal axis testing may be warranted to exclude other causes of secondary amenorrhea. Pelvic ultrasonography can provide information on ovarian morphology and antral follicle count. In the acute setting, interpretation of results may be confounded by the effects of critical illness on hormone levels; thus, repeat testing after clinical stabilization is often necessary.

Treatment & Management

Management of ovarian dysfunction in critically ill patients focuses on addressing the underlying illness, optimizing supportive care, and mitigating risk factors. Restoration of normal HPO axis function typically occurs following resolution of critical illness; however, persistent dysfunction may warrant endocrine consultation. Hormone replacement therapy (HRT) may be considered in women with prolonged hypoestrogenism to prevent sequelae such as osteoporosis, particularly if future fertility is not desired. Fertility preservation strategies, including oocyte or embryo cryopreservation, should be discussed with patients at high risk for persistent ovarian insufficiency, ideally prior to initiation of potentially gonadotoxic therapies. Multidisciplinary collaboration between intensivists, endocrinologists, and reproductive specialists is essential for individualized care planning.

Recent Advances / Emerging Therapies

Recent research has focused on early identification of women at risk for ovarian dysfunction and the development of protective strategies during critical illness. Anti-apoptotic and anti-inflammatory agents are under investigation for their potential to preserve ovarian reserve in the context of systemic inflammation. Innovative monitoring tools, such as serial AMH measurements, may enable risk stratification and guide fertility counseling. Advances in cryopreservation techniques now allow for greater flexibility in fertility preservation, even in acutely ill patients. The application of personalized medicine, including genetic risk profiling, holds promise for tailoring interventions to individual patient risk.

Guideline Recommendations

Current guidelines from reproductive and endocrine societies emphasize the importance of early recognition and management of ovarian dysfunction in the setting of critical illness. Recommendations include routine assessment of menstrual status in women of reproductive age admitted to the ICU, prompt evaluation of endocrine function in those with persistent symptoms, and consideration of fertility preservation in high-risk individuals. Multidisciplinary care and patient-centered counseling are paramount. The role of routine HRT is reserved for cases with prolonged or irreversible ovarian failure, and decisions should be individualized based on patient age, comorbidities, and reproductive goals.

Conclusion

Ovarian dysfunction is a significant and often under-recognized consequence of critical illness in women of reproductive age. Clinicians must maintain a high degree of vigilance for menstrual and hormonal disturbances in this population, integrating systematic assessment and multidisciplinary management. Advances in the understanding of pathophysiology, coupled with emerging diagnostic and therapeutic options, offer new opportunities for preserving reproductive health and improving long-term outcomes. Ongoing research and adherence to evidence-based guidelines will further inform best practices in this complex and evolving field.